|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Prostatic Acid Phosphatase (PAP)
Test Code208
CPT Codes
84066
Preferred Specimen
1 mL serum
Minimum Volume
0.5 mL
Instructions
Samples must be obtained before rectal examination, biopsy, prostatectomy or prostatic massage, since manipulating the prostate gland may lead to elevated PAP levels persisting up to 24-48 hours.
Specimens must be frozen if received by the laboratory greater than 24 hours after collection.
Specimens must be frozen if received by the laboratory greater than 24 hours after collection.
Transport Temperature
Frozen
Specimen Stability
Room temperature: 24 hours
Refrigerated: 24 hours
Frozen: 28 days
Refrigerated: 24 hours
Frozen: 28 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis
Methodology
Immunoassay (IA)
Setup Schedule
Set up: Mon-Sat; Report available: 1 day
Limitations
Prostatic message, urinary catheter, rectal examination, and other physical contact with the prostate may cause elevated results.
Reference Range
| Adult Male | <2.8 ng/mL |
Clinical Significance
High concentrations of acid phosphatase are found in the prostate gland. Significant amounts are also found in platelets, bone, spleen, kidney and liver. Prostatic Acid Phosphatase (PAP) is a component of total acid phosphates and is a major constituent in seminal fluid and is also secreted in the urine. PAP is normally found in serum in very low levels.
PAP measurement has found clinical application in the management of prostatic cancer patients. Serum PAP measurements have been useful in monitoring remission or relapse of a prostatic malignancy and in assessing the effectiveness of various treatment regimes. Thus, normalization in serum PAP levels has been observed following successful therapeutic intervention, while recurrent or residual disease has been associated with elevated levels of PAP.
PAP measurement has found clinical application in the management of prostatic cancer patients. Serum PAP measurements have been useful in monitoring remission or relapse of a prostatic malignancy and in assessing the effectiveness of various treatment regimes. Thus, normalization in serum PAP levels has been observed following successful therapeutic intervention, while recurrent or residual disease has been associated with elevated levels of PAP.
